A brief overview of cancer research in the elderly population

Authors

  • Juan Bautista De Sanctis Institute of Molecular and Translational Medicine. School of Medicine and Dentistry. Palacky University Olomouc. The Czech Republic. Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.
  • Jenny Garmendia Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.
  • Isaac Blanca Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.
  • Alexis García Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.
  • Michael Mijares Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.
  • Gricelis Martínez Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.
  • Daniela Cerezo-Wallis Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.
  • Camilo Di Giulio Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.
  • María Johanna Peña Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.
  • Marian Hajduch Institute of Molecular and Translational Medicine. School of Medicine and Dentistry. Palacky University Olomouc. The Czech Republic.
  • Danuta Radzioch Department of Experimental Medicine. McGill University. Montreal. Quebec. Canada
  • Nicolás Enrique Bianco Institute of Immunology. FOCIS Center of Excellence. School of Medicine. Universidad Central de Venezuela. Caracas. Venezuela.

Keywords:

Cancer, immune response, elderly population, valproic acid, disfulfiram, metformin, Cáncer, respuesta inmune, ancianos, ácido valproico, disulfiram, metformina

Abstract

Cancer is a complex disease and numerous treatments have been proposed and used. The breakthrough has been the use of biological therapy with checkpoint inhibitors, decreasing tumor burden. The life expectancy of cancer patients has increased. However, the major problem refers to the high incidence of tumors in the elderly population most of which have comorbidities.

El cáncer es una enfermedad compleja en el cual se han utilizado numerosos tratamientos. El mayor avance en tratamiento ha sido el uso de inhibidores de puntos de control, disminuyendo la carga tumoral. La esperanza de vida de los pacientes con cáncer ha aumentado. Sin embargo, se mantiene la alta incidencia de tumores en la población longeva, la mayoría de los cuales tienen comorbilidades.

Downloads

How to Cite

Bautista De Sanctis, J., Garmendia, J., Blanca, I., García, A., Mijares, M., Martínez, G., … Bianco, N. E. (2020). A brief overview of cancer research in the elderly population. Gaceta Médica De Caracas, 128(3), 290–295. Retrieved from https://saber.ucv.ve/ojs/index.php/rev_gmc/article/view/19358

Issue

Vol. 128 No. 3 (2020)

Section

ARTÍCULOS DE REVISIÓN

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.

Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.